Drugs / STX-721
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06043817 | Sep 2023 → Dec 2029 expected | non-small cell lung carcinoma | Pierre Fabre Laboratories | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06043817 ↗ |
| Known as | PFL-721 | “Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of...” NCT06043817 ↗ |